Drs. Queiro and Braña reply

REFERENCES

1. 1.↵
   1. Braña I,
   2. Loredo M,
   3. Pardo E,
   4. Burger S,
   5. Fernández-Bretón E,
   6. Queiro R.

   Patients with psoriatic arthritis-related enthesitis and persistence on tofacitinib under real-world conditions. J Rheumatol 2024;51:682-6.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Borrás-Blasco J,
   2. Valcuende-Rosique A,
   3. Cornejo-Uixeda S.

   Real-world persistence on tofacitinib in psoriatic arthritis patients with enthesitis: comments on recent findings. J Rheumatol 2025;52:1067-8.

   OpenUrlFREE Full Text
3. 3.↵
   1. Egeberg A,
   2. Rosenø NAL,
   3. Aagaard D, et al

   . Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 2022;53:151979.

   OpenUrlPubMed
4. 4.↵
   1. Hernández-Cruz B,
   2. Otero-Varela L,
   3. Freire-González M, et al; BIOBADASER Study Group

   . Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. Ann Rheum Dis 2024;83:1189-99.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Queiro R,
   2. Pinto-Tasende JA,
   3. Montilla-Morales C.

   Navigating psoriatic arthritis: treatment pathways and patient-specific strategies for improved outcomes. Drugs 2025; 85:867-82.

   OpenUrlPubMed
6. 6.↵
   1. Kharouf F,
   2. Gladman DD.

   Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies. Expert Rev Clin Immunol 2024;20:1381-400.

   OpenUrlPubMed